Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).
2013 ◽
Vol 31
(15_suppl)
◽
pp. LBA2010-LBA2010
◽
Keyword(s):
LBA2010 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Sunday, June, 2, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA5002-LBA5002
◽
Keyword(s):
2013 ◽
Vol 31
(15_suppl)
◽
pp. LBA10502-LBA10502
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA10008-LBA10008
◽
Keyword(s):
2013 ◽
Vol 31
(15_suppl)
◽
pp. 1-1
◽
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. 4-4
◽
Keyword(s):
2017 ◽
Vol 35
(15_suppl)
◽
pp. LBA10004-LBA10004
◽
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. CRA3503-CRA3503
◽
Keyword(s):
2013 ◽
Vol 31
(15_suppl)
◽
pp. LBA2000-LBA2000
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA8500-LBA8500
◽
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA4003-LBA4003
Keyword(s):